新型冠状病毒肺炎合并基础疾病患者抗病毒药物使用的药学监护策略

Pharmacological care strategy for antivirals in patients with COVID-19 complicated by underlying disorders

新型冠状病毒肺炎(COVID-19)在全球暴发,已对人民的身体健康及生命安全造成了严重威胁。合并基础疾病患者易重症化,在抗病毒治疗过程中,存在加重原有疾病、发生药物相互作用及出现药物不良反应等风险,因此非常有必要结合各类基础疾病特点提供个体化的药学监护。本文综合分析COVID-19抗病毒药物在不同基础疾病中的用药风险,总结了合并用药的相互作用及可能的不良反应,为伴随心血管疾病、慢性阻塞性肺病、器官移植、艾滋病及细菌真菌感染的COVID-19患者制定了药学监护策略,旨在提高COVID-19患者治疗方案的安全、合理及有效性。

The ongoing outbreak of COVID-19 has posed a serious threat to people’s health and life.Patients with underlying diseases are prone to severe disease.In the process of antiviral therapy,there are risks of aggravation of the original disease,drug interactions and adverse drug reactions.Therefore,it is very necessary to provide individualized pharmaceutical care in combination with the characteristics of various underlying diseases.The article comprehensively analyzed the medication risks of COVID-19 antiviral drugs in different underlying diseases,summarized the interactions and possible adverse reactions of concomitant drugs,and developed pharmaceutical care strategies for COVID-19 patients with cardiovascular diseases,chronic obstructive pulmonary disease,organ transplantation,AIDS and bacterial and fungal infections in order to improve the safety,rationality and effectiveness of treatment regimens for COVID-19 patients.